Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events

Evangelos Terpos; Suzanne Trudel; María‐Victoria Mateos; Nicolás Alejandre; Kathryn Colby; Meletios A Dimopoulos; Simona Degli Esposti; Asim V. Farooq; Maria Gavriatopoulou; Francesca Gay; Vânia Hungria; K. Martin Kortüm; Xavier Leleu; Sagar Lonial; Hang Quach; Lugui Qiu; Karthik Ramasamy; Kazuhito Suzuki; Katja Weisel; Paul G. Richardson

doi:10.1002/ajh.70015

Related publications

Article2024

Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis‐Papaiakovou, Giorgos Psarros, Efstathios Kastritis, Meletios A Dimopoulos

Article2025

Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).

Meral Beksac, Hang Quach, Vânia Hungria, Luděk Pour, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda, Ivan Špıčka, Marek Hus, Vera Zherebtsova, Margaret Polinkovsky, Sybil Varghese, Shing Yip Lee, Elisabet E. Manasanch, Paweł Robak, Meletios A Dimopoulos

Article2022

Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial

Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A Dimopoulos

Article2025

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials

María‐Victoria Mateos, Suzanne Trudel, Hang Quach, Paweł Robak, Meral Beksaç, Luděk Pour, Marek Hus, Kihyun Kım, Vera Zherebtsova, Sosana Delimpasi, Tomáš Jelı́nek, Christopher Wård, P. Joy Ho, Vladimir Vorobyev, Marcelo Pitombeira de Lacerda, Gracia Martínez, Ivan Špıčka, Jakub Radocha, Michèle Cavo, Claudio Cerchione, Chengcheng Fu, Kazuhito Suzuki, Rachel Rogers, Amy Phillips-Jones,

Article2023

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Foteini Theodorakakou, Vassiliki Spiliopoulou, Rodanthi‐Eleni Syrigou, Evangelos Eleutherakis‐Papaiakovou, S. Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A Dimopoulos, Evangelos Terpos